The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does ...

MIAMI, FLORIDA (EMBARGOED UNTIL MAY 25, 2023, AT 5 P.M. ET) – An early-phase study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...

Bench-to-bedside research led from preclinical experiments to a durable response among patients with a difficult-to-treat form of colorectal cancer Insights from single-cell sequencing of participant ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

Biomedical engineers have demonstrated that one of the most dangerous mutations found in skin cancers might moonlight as a pathway to mending a broken heart. The genetic mutation in the protein BRAF, ...

Researchers from Japan report that they have characterized gene mutations in colorectal cancer (CRC) tumors with high tumor mutation burden that lack mutations in the major oncogenes. Their findings ...